This disclosure generally relates to methods of treating copper-induced neurological damage observed in copper metabolism-associated diseases or disorders. This disclosure relates to reducing the copper-induced neurological damage in Wilson disease (WD).

The present invention relates to superstructured gold clusters Au-pX, consisting of gold atoms and at least one ligand, where said gold atoms in said cluster are in a number between 2 and 100 or the dimensions of said cluster are smaller than 2 nm, for use in the treatment of pathologies related to oxidative stress. In a preferred embodiment, said Au-pX superstructured gold clusters are for use in the treatment of Friedreich's ataxia.

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC corrected, alamine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

The present invention relates to a method for the evaluation of tissue gadolinium deposition that offers advantages compared with known methods. Comparison of different gadolinium-based contrast agents (GBCAs) based on retention, organ distribution, washout and safety is facilitated using the methods of the present invention.

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

The invention relates to methods, systems and kits for determining therapeutic effectiveness or toxicity of cancer-treating compounds that incorporate into or bind to DNA. In particular, the invention is directed to methods, systems and kits for predicting a patient's treatment outcome after administration of a microdose of therapeutic composition to the patient. The methods provides physicians with a diagnostic tool to segregate cancer patients into differential populations that have a higher or lower chance of responding to a particular therapeutic treatment.

The present invention relates to: a composition for wound healing, containing a metal-organic framework (MOF)as an active ingredient; and a wound dressing material comprising a hydrophilic superabsorbent polymer and the MOF, and the composition and the wound dressing material have a wound healing ability, specifically, the excellent effect of healing a wound by promoting fibroblast movement, do not significantly differ from a control group with respect to cytotoxicity, thereby exhibiting excellent safety when applied to a wound site, and have the excellent effect of having a wound recovery rate high enough to be checked with the naked eye over time.

The present invention relates to: a composition for wound healing, containing a metal-organic framework (MOF)as an active ingredient; and a wound dressing material comprising a hydrophilic superabsorbent polymer and the MOF, and the composition and the wound dressing material have a wound healing ability, specifically, the excellent effect of healing a wound by promoting fibroblast movement, do not significantly differ from a control group with respect to cytotoxicity, thereby exhibiting excellent safety when applied to a wound site, and have the excellent effect of having a wound recovery rate high enough to be checked with the naked eye over time.

Methods for treating Wilson Disease with bis-choline tetrathiomolybdate therapy are provided. The methods may include administering 15 mg or between 30 and 90 mg of bis-choline tetrathiomolybdate once daily to a patient exhibiting NCC.sub.corrected, alanine aminotransferase (ALT), hemoglobin, platelets, or neutrophils levels meeting specified criteria. The methods may include modifying treatment by decreasing or increasing the daily dose of bis-choline tetrathiomolybdate or discontinuing treatment for a period of time.

Disclosed herein are a variety of embodiments of compositions and methods which are each adapted for use by a companion animal. In one embodiment, an edible composition comprising an amount of a soluble mineral component is disclosed, wherein the soluble mineral component comprises one or more minerals selected from the group consisting of zinc, manganese, tin, copper, and mixtures thereof, wherein the amount is an effective amount for use as an oral medicament. In further embodiments, a phosphate component is included. The edible compositions are advantageously companion animal foods or supplements. Further disclosed are methods selected from treating oral cavity tartar, oral cavity plaque, periodontal disease, gingivitis, breath odor and combinations thereof comprising orally administering a described composition to a companion animal.